A.P. Pharma: PDUFA Date on APF530 Looms and I Am a Buyer (APPA.OB, $0.70)Thursday, January 24, 2013 · 10:49 am |
|
Recently Added Board Member Brings Great Expertise to the Potential Launch of APF530 (APPA, $0.64)Friday, September 28, 2012 · 9:33 am |
|
A.P. Pharma: Ondansetron’s Link to QT Interval Prolongation is a Huge Positive for APF530 (APPA, $0.68)Sunday, July 1, 2012 · 3:58 pm |
|
A.P. Pharma: Initiating Coverage with a Buy (APPA.OB, $0.42)Wednesday, April 25, 2012 · 4:22 pm |
|
There are 4 reports on file. |